BREAKWATER Study: Encorafenib, Cetuximab, and Chemotherapy for BRAF-Mutant mCRC

Opinion
Video

Christina Wu, MB, BCh, MD, shares data from the phase 3 BREAKWATER trial, which assesses first-line targeted treatment strategies for patients with BRAF V600E-mutant metastatic colorectal cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Optimal Sequencing Strategies for CAR T and Bispecifics in R/R MM
      Optimal Sequencing Strategies for CAR T and Bispecifics in R/R MM
      Role of Talquetamab as Bridging Therapy for CAR T-Cell Therapy
      Role of Talquetamab as Bridging Therapy for CAR T-Cell Therapy
      The CHALLENGE Trial Helps Redefine Adjuvant Therapy with Exercise in CRC
      The CHALLENGE Trial Helps Redefine Adjuvant Therapy with Exercise in CRC
      Strategic Sequencing in HER2+ Breast Cancer: Optimizing Treatment in the Third Line and Beyond
      Strategic Sequencing in HER2+ Breast Cancer: Optimizing Treatment in the Third Line and Beyond
      Patient Case Presentation: A 47-Year-Old Woman With HER2+ mBC and CNS Progression
      Patient Case Presentation: A 47-Year-Old Woman With HER2+ mBC and CNS Progression
      Outcomes and Factors for Consideration When Choosing Between CAR T Therapies
      Outcomes and Factors for Consideration When Choosing Between CAR T Therapies
      Late-Line R/R: Treatment Landscape
      Late-Line R/R: Treatment Landscape
      Strategies for Monitoring and Managing T-DXd-Related Adverse Effects
      Strategies for Monitoring and Managing T-DXd-Related Adverse Effects
      The Evolving Role of T-DXd in HER2+ Metastatic Breast Cancer
      The Evolving Role of T-DXd in HER2+ Metastatic Breast Cancer
      Optimizing Maintenance Therapy After First-Line Treatment in HER2+ Metastatic Breast Cancer
      Optimizing Maintenance Therapy After First-Line Treatment in HER2+ Metastatic Breast Cancer
      Related Content
      Exercise-Based Regimen Shows Efficacy Promise in CRC

      Exercise-Based Regimen Shows Efficacy Promise in CRC

      Ariana Pelosci
      June 30th 2025
      Article

      Nicholas J. Hornstein, MD, PhD, highlighted results from the phase 3 ATOMIC and CHALLENGE trials in CRC presented at the 2025 ASCO Annual Meeting.

      The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

      Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC

      Marwan G. Fakih, MD
      February 24th 2025
      Podcast

      The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.

      Investigators will submit detailed results from the phase 3 STELLAR-303 trial for presentation at a future medical conference.

      Zanzalintinib Combo Improves Survival vs Regorafenib in Metastatic CRC

      Russ Conroy
      June 23rd 2025
      Article

      Investigators will submit detailed results from the phase 3 STELLAR-303 trial for presentation at a future medical conference.

      Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

      Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval

      Jagoda Misniakiewicz, PharmD
      June 10th 2024
      Podcast

      Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.

      Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC

      Biweekly TAS-102 Reduces Toxicity, Maintains Survival in Metastatic CRC

      Tim Cortese
      June 17th 2025
      Article

      A retrospective analysis shows that trifluridine/tipiracil with or without bevacizumab given biweekly was favorable in those with colorectal cancer.

      In patients 39 years and younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.

      Adverse Sexual Health Outcomes Appear More Likely in Women With CRC

      Roman Fabbricatore
      June 12th 2025
      Article

      In patients 39 years or younger, a statistically significant association between colorectal cancer diagnosis and endometriosis was not observed.